Investor News


March 22, 2017
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 108th Annual Meeting:

Bayer to Showcase Data on Growing Oncology Pipeline at AACR 2017

more


March 18, 2017
Not intended for U.S. and UK Media - New Late-Breaking Study Data Presented at ACC.17:

Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

more


News Overview

 

New Investor

Your are interested in Bayer as a new investor? On this page you find helpful links to information on the company and our shares, latest financial reports and key figures, news and events, corporate governance, sustainability and services for investors.

New Investor

Highlights


Meet Management - London

Meet Management - London

FY/Q4 2016 All in One Package for Investors and Analysts

FY/Q4 2016 All in One Package for Investors and Analysts

Service for Investors and Analysts:
Download all documents on our Full Year and Fourth Quarter 2016 results in one ZIP file:
 
Download (ZIP, 13 MB) collect


Inside Information according to Article 17 MAR

Inside Information according to Article 17 MAR

Bayer: Phase III COMPASS study with Bayer’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early

Download (PDF, 66 KB) collect


Investor Conference Call: Bayer to Acquire Monsanto

Investor Conference Call: Bayer to Acquire Monsanto

Media conference call

Last updated: March 16, 2017 Copyright © Bayer AG